Tianxiang Zhang

Dr. Tianxiang Zhang

department of urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Pudong, Shanghai, China
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
YSYang Su
Yang Su
TZTianxiang Zhang
Tianxiang Zhang
JTJieqiong Tang
Jieqiong Tang
LZLi Zhang
Li Zhang
SFSong Fan
Song Fan
CLChaozhao Liang
Chaozhao Liang
Clear cell renal cell carcinoma (ccRCC) is a common malignancy with high distant metastasis rate. Long non-coding RNAs (LncRNAs) are reported to be upregulated or downregulated in multiple cancers and play a crucial role in the metastasis of tumors or prognosis. Therefore, the purpose of our study is to construct a prognostic signature for ccRCC based on distant metastasis-related lncRNAs and explore the involved potential competitive endogenous RNA (ceRNA) network. The differentially expressed genes (DEGs) screened from the database of the cancer genome atlas (TCGA) were used to construct a co-expression network and identify the distant metastasis-related module by weighted gene co-expression network analysis (WGCNA). Key genes with metastatic and prognostic significance were identified through rigorous screening, including survival analysis, correlation analysis, and expression analyses in stage, grade, and distant metastasis, and were verified in the data set of gene expression omnibus (GEO) and the database from gene expression profiling interactive analysis (GEPIA). The potential upstream miRNAs and lncRNAs were predicted via five online databases and LncBase. Here, we constructed a ceRNA network of key genes that are significantly associated with the distant metastasis and prognosis of patients with ccRCC. The distant metastasis-related lncRNAs were used to construct a risk score model through the univariate, least absolute shrinkage selection operator (LASSO), and multivariate Cox regression analyses, and the patients were divided into high- and low-risk groups according to the median of the risk score. The Kaplan–Meier survival analysis demonstrated that mortality was significantly higher in the high-risk group than in the low-risk group. Considering the other clinical phenotype, the Cox regression analyses indicated that the lncRNAs model could function as an independent prognostic factor. Quantitative real-time (qRT)-PCR in the tissues and cells of ccRCC verified the high-expression level of three lncRNAs. Gene set enrichment analysis (GSEA) revealed that the lncRNA prognostic signature was mainly enriched in autophagy- and immune-related pathways, indicating that the autophagy and immune functions may play an important role in the distant metastasis of ccRCC. In summary, the constructed distant metastasis-related lncRNA signature could independently predict prognosis in patients with ccRCC, and the related ceRNA network provided a new sight on the potential mechanism of distant metastasis and a promising therapeutic target for ccRCC.

18 June 2021 in Lupus
Verified
Journal Article
Closed access
PDF file
HZHao-Yue Zhou
Hao-Yue Zhou
NCNv-Wei Cao
Nv-Wei Cao
BGBiao Guo
Biao Guo
WCWen-Jun Chen
Wen-Jun Chen
JTJin-Hui Tao
Jin-Hui Tao
BLBao-Zhu Li
Bao-Zhu Li
The skin is the second most affected organ after articular involvement in systemic lupus erythematosus (SLE) patients. Cutaneous involvement occurs in approximately 80% of patients during the course of SLE. Interaction between the host and skin microorganism is a complex process. There are few studies on the diversity of skin microbes in SLE patients. Therefore, this study aims to explore the relationship between skin microorganisms and SLE. A total of 20 SLE patients, 20 controls with rosacea and 20 healthy controls were selected as study subjects. Both the skin microbiota of rash region and non-rash region for each SLE patient were collected.16S rRNA gene sequencing was used to detected skin microbiota from 80 specimens. α-Diversity and β-diversity of skin microbiota were analyzed based on operational taxonomic units (OTUs) and minimal entropy decomposition (MED). Using Wilcoxon test and Linear Discriminate Analysis Effect Size (LEfSe), skin microbial diversity and composition were analyzed. Functional capabilities of microbiota were estimated through Kyoto Encyclopedia of Genes and Genomes database. Compared to rash region of SLE, diversity and richness were increased in healthy controls, and decreased in non-rash region of SLE and rash region of controls with rosacea. Additionally, changes of skin microbial composition were found at different taxonomic levels between four groups. For example, genus Halomonas was increased and genera Pelagibacterium, Novosphingobium, and Curvibacter were decreased in rash region compared to non-rash region of SLE based on OTUs and MED. Based on OTUs, metabolic pathways were also found differences in SLE patients, such as Xenobiotics Biodegradation and Metabolism. Compositions and diversity of skin microbiota in SLE patients are changed. This pilot study provides some suggestive evidence for further exploration of skin microbiota in SLE patients with cutaneous involvement.

1 January 2023 in Cells
Verified
Journal Article
Open access
PDF file
YSYang Su
Yang Su
TZTianxiang Zhang
Tianxiang Zhang
JLJinsen Lu
Jinsen Lu
LQLei Qian
Lei Qian
FYFei Yang
Fei Yang
CLChaozhao Liang
Chaozhao Liang
Clear cell renal cell carcinoma (ccRCC) has a high metastatic rate, and its incidence and mortality are still rising. The aim of this study was to identify the key tumor-infiltrating immune cells (TIICs) affecting the distant metastasis and prognosis of patients with ccRCC and to construct a relevant prognostic panel to predict immunotherapy response. Based on ccRCC bulk RNA sequencing data, resting mast cells (RMCs) were screened and verified using the CIBERSORT algorithm, survival analysis, and expression analysis. Distant metastasis-associated genes were identified using single-cell RNA sequencing data. Subsequently, a three-gene (CFB, PPP1R18, and TOM1L1) panel with superior distant metastatic and prognostic performance was established and validated, which stratified patients into high- and low-risk groups. The high-risk group exhibited lower infiltration of RMCs, higher tumor mutation burden (TMB), and worse prognosis. Therapeutically, the high-risk group was more sensitive to anti-PD-1 and anti-CTLA-4 immunotherapy, whereas the low-risk group displayed a better response to anti-PD-L1 immunotherapy. Furthermore, two immune clusters revealing distinct immune, clinical, and prognosis heterogeneity were distinguished. Immunohistochemistry of ccRCC samples verified the expression patterns of the three key genes. Collectively, the prognostic panel based on RMCs is able to predict distant metastasis and immunotherapy response in patients with ccRCC, providing new insight for the treatment of advanced ccRCC.

3 September 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JZJingyu Zang
Jingyu Zang
ASAkezhouli Shahatiaili
Akezhouli Shahatiaili
MCMei-Chun Cai
Mei-Chun Cai
DJDi Jin
Di Jin
PSPeiye Shen
Peiye Shen
HCHaige Chen
Haige Chen
Purpose: Neuroendocrine bladder cancer (NEBC) poses a formidable clinical challenge and attracts keen interests to explore immunotherapy as a viable treatment option. However, a comprehensive immunogenomic landscape has yet to be thoroughly investigated. Experimental Design: Leveraging a long-term cohort of natural NEBC cases, we employed a multimodal approach integrating genomic (n = 19), transcriptomic (n = 3), single-cell RNA sequencing (n = 1), and IHC analyses (n = 34) to meticulously characterize the immunogenicity and immunotypes of primary NEBC tumors. Information on clinical, pathologic, medical imaging, and treatment aspects was retrospectively retrieved and analyzed. Results: Our study unveiled that despite a considerable mutational burden, NEBC was typically immunologically inactive, as manifested by the “immune-excluded” or “immune-desert” microenvironment. Interestingly, a subset of mixed NEBC with concurrent urothelial bladder cancer histology displayed an “immune-infiltrated” phenotype with prognostic relevance. When compared with urothelial bladder cancer, NEBC lesions were distinguished by a denser cellular composition and augmented peritumoral extracellular matrix, which might collectively impede lymphatic infiltration. As a result, single-agent immune checkpoint inhibitors demonstrated limited efficacy against NEBC, whereas pharmacologic immunostimulation with combination chemotherapy conferred a more favorable response. Conclusions: These new insights derived from genomic profiling and immune phenotyping pave the way for rational immunotherapeutic interventions in patients with NEBC, with the potential to ultimately reduce mortality from this otherwise fatal disease.

1 November 2024
Verified
Other
Open access
PDF file
JZJingyu Zang
Jingyu Zang
ASAkezhouli Shahatiaili
Akezhouli Shahatiaili
MCMei-Chun Cai
Mei-Chun Cai
DJDi Jin
Di Jin
PSPeiye Shen
Peiye Shen
HCHaige Chen
Haige Chen
Immunotype distribution and fibrotic barriers in NEBC.

1 November 2024
Verified
Other
Open access
JZJingyu Zang
Jingyu Zang
ASAkezhouli Shahatiaili
Akezhouli Shahatiaili
MCMei-Chun Cai
Mei-Chun Cai
DJDi Jin
Di Jin
PSPeiye Shen
Peiye Shen
HCHaige Chen
Haige Chen
Table S1. Quality control of sequencing data. Table S2. Representativeness of study participants. Table S3. Clinicopathological characteristics of 35 patients diagnosed with NEBC. Table S4. Summary of clinicopathological characteristics for the NEBC cohort. Table S5. Comparing clinical characteristics of patients in the NEBC and UBC cohort before and after PSM. Table S6. Whole genome sequencing statistics of 19 patients in NEBC cohort. Table S7. Density of immune cells in CT and IM region and immunotypes of patients in NEBC cohort. Table S8. Cell density and Ki-67 expresion in NEBC region and UBC region of patients diagnosed with mixed-UBC. Table S9. Clinical characteristics of metastatic NEBC patients receiving systemic treatment. Table S10. Clinical characteristics and density of immune cells of patients receiving neoadjuvant treatment.